CSI Market
Sign In | Register

Eiger Biopharmaceuticals Inc (EIGR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EIGR Annual Cash Flow →
From Eiger Biopharmaceuticals Inc through Dec 31 2022, changes in Dec 31 2023's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		(Sep 30 2023) (Jun 30 2023) (Mar 31 2023) (Dec 31 2022)
Operating Activities
Income-74.96
Depreciation & amortization0.28
Amortization of Other Assets1.49
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase1.63
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation5.01
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Change In Fair Value Of Obligation To Issue Common Stock-
Change In Fair Value Of Obligation To Issue Shares-
Operating Lease Right Of Use Asset Amortization-
Gain Loss From Sale Of Priority Review Voucher-
Income Loss Related To Asset Purchase Agreement-
Operating Lease Right Of Use Asset Amortization Expense0.35
Increase Decrease In Prepaid Expenses And Other Current Assets0.42
Increase Decrease In Operating Lease Liabilities-0.37
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.08
Increase (Decrease) in Accounts Payable-6.84
Increase (Decrease) in Accrued Liabilities-6.15
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital1.86
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.11
Discontinued operations0.00
Net Cash flow from Operating Activities-74.55
Investing Activities
Capital Expenditures-0.23
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities93.85
Payments to Acquire Available-for-sale Securities, Debt-19.39
Real Estate Investments0.00
Proceeds From Reverse Merger-
Proceeds From Sale Of Priority Review Voucher-
Payments Related To Priority Review Voucher-
Proceeds Related To Asset Purchase Agreement-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities74.23
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.04
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Repayment Of Accrued Exit Fee And Second Amendment Fee-
Payments Of Deferred Offering Costs-
Payments Of Common Stock Offering Costs-
Proceeds From Issuance Of Common Stock In Connection With Debt-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.04
Effect of exchange rate on cash flow-0.08
Discontinued operations0.00
Free Cash Flow-74.78
Total Cash Flow-0.36
4 historic quarters locked

Sign in to unlock the full Eiger Biopharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Eiger Biopharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-24-015297

Figures are derived from filed reports and may be restated. Historical data is subject to revision.